Search

Andrew W. Johns

Examiner (ID: 13016, Phone: (571)272-7391 , Office: P/2665 )

Most Active Art Unit
2665
Art Unit(s)
2624, 2606, 2662, 2714, 2621, 2665, 2616, 2721, 2899
Total Applications
2451
Issued Applications
2078
Pending Applications
135
Abandoned Applications
240

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18289889 [patent_doc_number] => 11618751 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-04-04 [patent_title] => Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives [patent_app_type] => utility [patent_app_number] => 17/704983 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16076 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17704983 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/704983
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives Mar 24, 2022 Issued
Array ( [id] => 18134728 [patent_doc_number] => 11560381 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-01-24 [patent_title] => Compounds and uses thereof [patent_app_type] => utility [patent_app_number] => 17/696656 [patent_app_country] => US [patent_app_date] => 2022-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 76934 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 590 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17696656 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/696656
Compounds and uses thereof Mar 15, 2022 Issued
Array ( [id] => 17867010 [patent_doc_number] => 20220289745 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/692923 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17692923 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/692923
Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors Mar 10, 2022 Issued
Array ( [id] => 17704500 [patent_doc_number] => 20220204506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/692695 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21042 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17692695 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/692695
Crystalline salts of a B-RAF kinase inhibitor Mar 10, 2022 Issued
Array ( [id] => 18151979 [patent_doc_number] => 11564928 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-01-31 [patent_title] => Cannabinoid receptor type 2 (CB2) modulators and uses thereof [patent_app_type] => utility [patent_app_number] => 17/691991 [patent_app_country] => US [patent_app_date] => 2022-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 89815 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17691991 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/691991
Cannabinoid receptor type 2 (CB2) modulators and uses thereof Mar 9, 2022 Issued
Array ( [id] => 20213524 [patent_doc_number] => 12410166 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors [patent_app_type] => utility [patent_app_number] => 18/040129 [patent_app_country] => US [patent_app_date] => 2022-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16832 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040129 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/040129
Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors Mar 3, 2022 Issued
Array ( [id] => 18916706 [patent_doc_number] => 11878976 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-23 [patent_title] => FGFR3 inhibitor compounds [patent_app_type] => utility [patent_app_number] => 17/685753 [patent_app_country] => US [patent_app_date] => 2022-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58475 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 593 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17685753 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/685753
FGFR3 inhibitor compounds Mar 2, 2022 Issued
Array ( [id] => 17867009 [patent_doc_number] => 20220289744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/682763 [patent_app_country] => US [patent_app_date] => 2022-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17682763 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/682763
IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES Feb 27, 2022 Abandoned
Array ( [id] => 17959987 [patent_doc_number] => 20220340567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/679898 [patent_app_country] => US [patent_app_date] => 2022-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17679898 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/679898
COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF Feb 23, 2022 Abandoned
Array ( [id] => 19202763 [patent_doc_number] => 20240174662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES [patent_app_type] => utility [patent_app_number] => 18/263432 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 106362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18263432 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/263432
SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Jan 30, 2022 Pending
Array ( [id] => 17749551 [patent_doc_number] => 20220227755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/589072 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 273 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17589072 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/589072
SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS Jan 30, 2022 Abandoned
Array ( [id] => 19003559 [patent_doc_number] => 20240067630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS [patent_app_type] => utility [patent_app_number] => 18/255247 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255247 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/255247
ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS Jan 30, 2022 Pending
Array ( [id] => 19187731 [patent_doc_number] => 20240166644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/263249 [patent_app_country] => US [patent_app_date] => 2022-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38833 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18263249 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/263249
Sulfonyl benzamide derivatives as Bcl-2 inhibitors Jan 29, 2022 Issued
Array ( [id] => 18887683 [patent_doc_number] => 11866444 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Oxabicycloheptane prodrugs [patent_app_type] => utility [patent_app_number] => 17/586548 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 30847 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586548 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/586548
Oxabicycloheptane prodrugs Jan 26, 2022 Issued
Array ( [id] => 17749550 [patent_doc_number] => 20220227754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => AMPK ACTIVATORS [patent_app_type] => utility [patent_app_number] => 17/584831 [patent_app_country] => US [patent_app_date] => 2022-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17584831 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/584831
AMPK activators Jan 25, 2022 Issued
Array ( [id] => 20040840 [patent_doc_number] => 20250179062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-05 [patent_title] => CRYSTALLINE FORMS OF A PYRROLOPYRIDINE-ANILINE COMPOUND [patent_app_type] => utility [patent_app_number] => 18/273315 [patent_app_country] => US [patent_app_date] => 2022-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273315 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/273315
CRYSTALLINE FORMS OF A PYRROLOPYRIDINE-ANILINE COMPOUND Jan 19, 2022 Pending
Array ( [id] => 19127161 [patent_doc_number] => 20240132514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => PYRIDINE DERIVATIVES AS MODULATORS OF SORTILIN ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/273225 [patent_app_country] => US [patent_app_date] => 2022-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273225 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/273225
PYRIDINE DERIVATIVES AS MODULATORS OF SORTILIN ACTIVITY Jan 19, 2022 Pending
Array ( [id] => 18034566 [patent_doc_number] => 20220378781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => METHODS OF TREATING PSYCHIATRIC DISORDERS IN OBESE PATIENTS WITH BREXPIPRAZOLE [patent_app_type] => utility [patent_app_number] => 17/575316 [patent_app_country] => US [patent_app_date] => 2022-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17575316 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/575316
Methods of treating psychiatric disorders in obese patients with brexpiprazole Jan 12, 2022 Issued
Array ( [id] => 17937023 [patent_doc_number] => 11471455 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Compounds and compositions for treating conditions associated with APJ receptor activity [patent_app_type] => utility [patent_app_number] => 17/572531 [patent_app_country] => US [patent_app_date] => 2022-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67863 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17572531 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/572531
Compounds and compositions for treating conditions associated with APJ receptor activity Jan 9, 2022 Issued
Array ( [id] => 18895161 [patent_doc_number] => 20240010646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => Urea Co-Crystal of Apixaban, and Preparation Method Therefor [patent_app_type] => utility [patent_app_number] => 18/004276 [patent_app_country] => US [patent_app_date] => 2021-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18004276 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/004276
Urea Co-Crystal of Apixaban, and Preparation Method Therefor Dec 23, 2021 Abandoned
Menu